Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

Similar articles for PubMed (Select 22897063)

1.

Potential impact of policy regulation and generic competition on sales of cholesterol lowering medication, antidepressants and acid blocking agents in Belgium.

Fraeyman J, Van Hal G, De Loof H, Remmen R, De Meyer GR, Beutels P.

Acta Clin Belg. 2012 May-Jun;67(3):160-71.

PMID:
22897063
2.

Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.

Fraeyman J, Verbelen M, Hens N, Van Hal G, De Loof H, Beutels P.

Appl Health Econ Health Policy. 2013 Oct;11(5):543-52. doi: 10.1007/s40258-013-0054-9.

PMID:
24062144
3.

The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium.

Fraeyman J, Van Hal G, Godman B, Beutels P.

Expert Rev Pharmacoecon Outcomes Res. 2013 Feb;13(1):141-51. doi: 10.1586/erp.12.88.

PMID:
23402454
4.

Impact of European pharmaceutical price regulation on generic price competition: a review.

Puig-Junoy J.

Pharmacoeconomics. 2010;28(8):649-63. doi: 10.2165/11535360-000000000-00000. Review.

PMID:
20515079
5.

European healthcare policies for controlling drug expenditure.

Ess SM, Schneeweiss S, Szucs TD.

Pharmacoeconomics. 2003;21(2):89-103.

PMID:
12515571
6.

Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea.

Bae G, Park C, Lee H, Han E, Kim DS, Jang S.

BMC Health Serv Res. 2014 Mar 3;14:100. doi: 10.1186/1472-6963-14-100.

7.

Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs.

Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A.

Expert Rev Pharmacoecon Outcomes Res. 2011 Feb;11(1):121-9. doi: 10.1586/erp.10.87.

PMID:
21351864
8.

Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.

Mansfield SJ.

Aust Health Rev. 2014 Feb;38(1):6-15. doi: 10.1071/AH12009.

PMID:
24480618
9.

Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications.

Woerkom Mv, Piepenbrink H, Godman B, Metz Jd, Campbell S, Bennie M, Eimers M, Gustafsson LL.

J Comp Eff Res. 2012 Nov;1(6):527-38. doi: 10.2217/cer.12.52.

PMID:
24236472
10.

The impact of reference-pricing systems in Europe: a literature review and case studies.

Dylst P, Vulto A, Simoens S.

Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(6):729-37. doi: 10.1586/erp.11.70. Review.

PMID:
22098289
12.

Pharmaceutical policy regarding generic drugs in Belgium.

Simoens S, De Bruyn K, Bogaert M, Laekeman G.

Pharmacoeconomics. 2005;23(8):755-66.

PMID:
16097838
13.

The impact of generic reference pricing interventions in the statin market.

Puig-Junoy J.

Health Policy. 2007 Nov;84(1):14-29. Epub 2007 Mar 26.

PMID:
17368619
14.
15.

Utilization, price, and spending trends for antidepressants in the US Medicaid Program.

Chen Y, Kelton CM, Jing Y, Guo JJ, Li X, Patel NC.

Res Social Adm Pharm. 2008 Sep;4(3):244-57. doi: 10.1016/j.sapharm.2007.06.019. Epub 2008 Aug 8.

PMID:
18794035
16.

Antidepressant utilization in primary care in a Spanish region: impact of generic and reference-based pricing policy (2000-2004).

Ubeda A, Cardo E, Sellés N, Broseta R, Trillo JL, Fernández-Llimós F.

Soc Psychiatry Psychiatr Epidemiol. 2007 Mar;42(3):181-8. Epub 2007 Jan 17.

PMID:
17235443
17.

The relationship of antidepressant prescribing concentration to treatment duration and cost.

Hodgkin D, Merrick EL, Hiatt D.

J Ment Health Policy Econ. 2012 Mar;15(1):3-11.

18.

Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi.

Abuelkhair M, Abdu S, Godman B, Fahmy S, Malmström RE, Gustafsson LL.

Expert Rev Pharmacoecon Outcomes Res. 2012 Feb;12(1):115-24. doi: 10.1586/erp.11.90.

PMID:
22280201
19.

Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses.

Leopold C, Zhang F, Mantel-Teeuwisse AK, Vogler S, Valkova S, Ross-Degnan D, Wagner AK.

Int J Equity Health. 2014 Jul 25;13:53. doi: 10.1186/1475-9276-13-53.

20.

An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts.

Berndt ER, Bhattacharjya A, Mishol DN, Arcelus A, Lasky T.

J Ment Health Policy Econ. 2002 Mar;5(1):3-19.

PMID:
12529566
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk